AbbVie Inc. (NYSE: ABBV) Stock Competitors & Peer Comparison
See ABBV's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ABBV and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ABBV | $262.69 | +4.94% | 457.5B | 25.41 | $10.19 | +2.65% |
| LLY | $1,268.99 | +7.25% | 1.2T | 38.95 | $31.49 | +0.55% |
| JNJ | $272.28 | +3.78% | 653.4B | 25.27 | $10.73 | +1.94% |
| MRK | $150.09 | +10.39% | 333.8B | 42.11 | $3.21 | +2.48% |
| NVS | $158.72 | +4.44% | 293.9B | 17.79 | $8.69 | +3.06% |
| AZN | $164.37 | +4.77% | 248.3B | 17.29 | $9.26 | +1.30% |
| AMGN | $437.18 | +4.24% | 229.5B | 19.01 | $22.37 | +2.30% |
| NVO | $46.33 | +3.23% | 202.9B | 11.37 | $4.02 | +2.54% |
| GILD | $146.88 | +5.73% | 178.1B | -367.79 | -$0.39 | +2.25% |
| PFE | $28.07 | +4.45% | 155.4B | 8.94 | $3.05 | +6.30% |
Stock Comparison
Eli Lilly and Company (NYSE: LLY)
ABBV vs LLY Comparison August 2026
AbbVie Inc. (NYSE: ABBV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 457.5B. In comparison, LLY has a market cap of 1.2T. Regarding current trading prices, ABBV is priced at $262.69 on the NYSE, while LLY trades at $1,268.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 25.41, whereas LLY's P/E ratio is 38.95. In terms of profitability, ABBV's ROE is -1.36%, compared to LLY's ROE of +0.93%. Regarding short-term risk, ABBV is less volatile compared to LLY. This indicates lower risk in terms of short-term price fluctuations for ABBV.Check LLY's competition here
Johnson & Johnson (NYSE: JNJ)
ABBV vs JNJ Comparison August 2026
AbbVie Inc. (NYSE: ABBV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 457.5B. In comparison, JNJ has a market cap of 653.4B. Regarding current trading prices, ABBV is priced at $262.69 on the NYSE, while JNJ trades at $272.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 25.41, whereas JNJ's P/E ratio is 25.27. In terms of profitability, ABBV's ROE is -1.36%, compared to JNJ's ROE of +0.26%. Regarding short-term risk, ABBV is more volatile compared to JNJ. This indicates higher risk in terms of short-term price fluctuations for ABBV.Check JNJ's competition here
Merck & Co., Inc. (NYSE: MRK)
ABBV vs MRK Comparison August 2026
AbbVie Inc. (NYSE: ABBV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 457.5B. In comparison, MRK has a market cap of 333.8B. Regarding current trading prices, ABBV is priced at $262.69 on the NYSE, while MRK trades at $150.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 25.41, whereas MRK's P/E ratio is 42.11. In terms of profitability, ABBV's ROE is -1.36%, compared to MRK's ROE of +0.07%. Regarding short-term risk, ABBV is less volatile compared to MRK. This indicates lower risk in terms of short-term price fluctuations for ABBV.Check MRK's competition here
Novartis AG (NYSE: NVS)
ABBV vs NVS Comparison August 2026
AbbVie Inc. (NYSE: ABBV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 457.5B. In comparison, NVS has a market cap of 293.9B. Regarding current trading prices, ABBV is priced at $262.69 on the NYSE, while NVS trades at $158.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 25.41, whereas NVS's P/E ratio is 17.79. In terms of profitability, ABBV's ROE is -1.36%, compared to NVS's ROE of +0.30%. Regarding short-term risk, ABBV is more volatile compared to NVS. This indicates higher risk in terms of short-term price fluctuations for ABBV.Check NVS's competition here
AstraZeneca PLC (NYSE: AZN)
ABBV vs AZN Comparison August 2026
AbbVie Inc. (NYSE: ABBV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 457.5B. In comparison, AZN has a market cap of 248.3B. Regarding current trading prices, ABBV is priced at $262.69 on the NYSE, while AZN trades at $164.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 25.41, whereas AZN's P/E ratio is 17.29. In terms of profitability, ABBV's ROE is -1.36%, compared to AZN's ROE of +0.22%. Regarding short-term risk, ABBV is more volatile compared to AZN. This indicates higher risk in terms of short-term price fluctuations for ABBV.Check AZN's competition here
Amgen Inc. (NASDAQ: AMGN)
ABBV vs AMGN Comparison August 2026
AbbVie Inc. (NYSE: ABBV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 457.5B. In comparison, AMGN has a market cap of 229.5B. Regarding current trading prices, ABBV is priced at $262.69 on the NYSE, while AMGN trades at $437.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 25.41, whereas AMGN's P/E ratio is 19.01. In terms of profitability, ABBV's ROE is -1.36%, compared to AMGN's ROE of +0.89%. Regarding short-term risk, ABBV is less volatile compared to AMGN. This indicates lower risk in terms of short-term price fluctuations for ABBV.Check AMGN's competition here
Novo Nordisk A/S (NYSE: NVO)
ABBV vs NVO Comparison August 2026
AbbVie Inc. (NYSE: ABBV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 457.5B. In comparison, NVO has a market cap of 202.9B. Regarding current trading prices, ABBV is priced at $262.69 on the NYSE, while NVO trades at $46.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 25.41, whereas NVO's P/E ratio is 11.37. In terms of profitability, ABBV's ROE is -1.36%, compared to NVO's ROE of +0.59%. Regarding short-term risk, ABBV is less volatile compared to NVO. This indicates lower risk in terms of short-term price fluctuations for ABBV.Check NVO's competition here
Gilead Sciences, Inc. (NASDAQ: GILD)
ABBV vs GILD Comparison August 2026
AbbVie Inc. (NYSE: ABBV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 457.5B. In comparison, GILD has a market cap of 178.1B. Regarding current trading prices, ABBV is priced at $262.69 on the NYSE, while GILD trades at $146.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 25.41, whereas GILD's P/E ratio is -367.79. In terms of profitability, ABBV's ROE is -1.36%, compared to GILD's ROE of -0.16%. Regarding short-term risk, ABBV is less volatile compared to GILD. This indicates lower risk in terms of short-term price fluctuations for ABBV.Check GILD's competition here
Pfizer Inc. (NYSE: PFE)
ABBV vs PFE Comparison August 2026
AbbVie Inc. (NYSE: ABBV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 457.5B. In comparison, PFE has a market cap of 155.4B. Regarding current trading prices, ABBV is priced at $262.69 on the NYSE, while PFE trades at $28.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 25.41, whereas PFE's P/E ratio is 8.94. In terms of profitability, ABBV's ROE is -1.36%, compared to PFE's ROE of +0.05%. Regarding short-term risk, ABBV is less volatile compared to PFE. This indicates lower risk in terms of short-term price fluctuations for ABBV.Check PFE's competition here
Bristol-Myers Squibb Company (NYSE: BMY)
ABBV vs BMY Comparison August 2026
AbbVie Inc. (NYSE: ABBV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 457.5B. In comparison, BMY has a market cap of 132.1B. Regarding current trading prices, ABBV is priced at $262.69 on the NYSE, while BMY trades at $67.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 25.41, whereas BMY's P/E ratio is 10.90. In terms of profitability, ABBV's ROE is -1.36%, compared to BMY's ROE of +0.47%. Regarding short-term risk, ABBV is less volatile compared to BMY. This indicates lower risk in terms of short-term price fluctuations for ABBV.Check BMY's competition here
Sanofi (NASDAQ: SNY)
ABBV vs SNY Comparison August 2026
AbbVie Inc. (NYSE: ABBV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 457.5B. In comparison, SNY has a market cap of 108B. Regarding current trading prices, ABBV is priced at $262.69 on the NYSE, while SNY trades at $45.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 25.41, whereas SNY's P/E ratio is 9.80. In terms of profitability, ABBV's ROE is -1.36%, compared to SNY's ROE of +0.06%. Regarding short-term risk, ABBV is more volatile compared to SNY. This indicates higher risk in terms of short-term price fluctuations for ABBV.Check SNY's competition here
GSK plc (NYSE: GSK)
ABBV vs GSK Comparison August 2026
AbbVie Inc. (NYSE: ABBV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 457.5B. In comparison, GSK has a market cap of 102.5B. Regarding current trading prices, ABBV is priced at $262.69 on the NYSE, while GSK trades at $52.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 25.41, whereas GSK's P/E ratio is 11.05. In terms of profitability, ABBV's ROE is -1.36%, compared to GSK's ROE of +0.24%. Regarding short-term risk, ABBV is less volatile compared to GSK. This indicates lower risk in terms of short-term price fluctuations for ABBV.Check GSK's competition here
Zoetis Inc. (NYSE: ZTS)
ABBV vs ZTS Comparison August 2026
AbbVie Inc. (NYSE: ABBV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 457.5B. In comparison, ZTS has a market cap of 31B. Regarding current trading prices, ABBV is priced at $262.69 on the NYSE, while ZTS trades at $76.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 25.41, whereas ZTS's P/E ratio is 11.24. In terms of profitability, ABBV's ROE is -1.36%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, ABBV is less volatile compared to ZTS. This indicates lower risk in terms of short-term price fluctuations for ABBV.Check ZTS's competition here
Biogen Inc. (NASDAQ: BIIB)
ABBV vs BIIB Comparison August 2026
AbbVie Inc. (NYSE: ABBV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 457.5B. In comparison, BIIB has a market cap of 30.9B. Regarding current trading prices, ABBV is priced at $262.69 on the NYSE, while BIIB trades at $218.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 25.41, whereas BIIB's P/E ratio is 13.20. In terms of profitability, ABBV's ROE is -1.36%, compared to BIIB's ROE of +0.05%. Regarding short-term risk, ABBV is more volatile compared to BIIB. This indicates higher risk in terms of short-term price fluctuations for ABBV.Check BIIB's competition here
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP)
ABBV vs HZNP Comparison August 2026
AbbVie Inc. (NYSE: ABBV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 457.5B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, ABBV is priced at $262.69 on the NYSE, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 25.41, whereas HZNP's P/E ratio is 61.86. In terms of profitability, ABBV's ROE is -1.36%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, ABBV is more volatile compared to HZNP. This indicates higher risk in terms of short-term price fluctuations for ABBV.Check HZNP's competition here
Grifols, S.A. (NASDAQ: GRFS)
ABBV vs GRFS Comparison August 2026
AbbVie Inc. (NYSE: ABBV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 457.5B. In comparison, GRFS has a market cap of 6.6B. Regarding current trading prices, ABBV is priced at $262.69 on the NYSE, while GRFS trades at $8.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 25.41, whereas GRFS's P/E ratio is 8.90. In terms of profitability, ABBV's ROE is -1.36%, compared to GRFS's ROE of +0.08%. Regarding short-term risk, ABBV is less volatile compared to GRFS. This indicates lower risk in terms of short-term price fluctuations for ABBV.Check GRFS's competition here
Organon & Co. (NYSE: OGN)
ABBV vs OGN Comparison August 2026
AbbVie Inc. (NYSE: ABBV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 457.5B. In comparison, OGN has a market cap of 3.6B. Regarding current trading prices, ABBV is priced at $262.69 on the NYSE, while OGN trades at $13.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 25.41, whereas OGN's P/E ratio is 4.08. In terms of profitability, ABBV's ROE is -1.36%, compared to OGN's ROE of +0.23%. Regarding short-term risk, ABBV is more volatile compared to OGN. This indicates higher risk in terms of short-term price fluctuations for ABBV.Check OGN's competition here
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI)
ABBV vs CELG-RI Comparison August 2026
AbbVie Inc. (NYSE: ABBV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 457.5B. In comparison, CELG-RI has a market cap of 224.5M. Regarding current trading prices, ABBV is priced at $262.69 on the NYSE, while CELG-RI trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 25.41, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, ABBV's ROE is -1.36%, compared to CELG-RI's ROE of N/A. Regarding short-term risk, ABBV is more volatile compared to CELG-RI. This indicates higher risk in terms of short-term price fluctuations for ABBV.Check CELG-RI's competition here
Citius Oncology, Inc. (NASDAQ: CTOR)
ABBV vs CTOR Comparison August 2026
AbbVie Inc. (NYSE: ABBV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 457.5B. In comparison, CTOR has a market cap of 67M. Regarding current trading prices, ABBV is priced at $262.69 on the NYSE, while CTOR trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 25.41, whereas CTOR's P/E ratio is -1.53. In terms of profitability, ABBV's ROE is -1.36%, compared to CTOR's ROE of -1.03%. Regarding short-term risk, ABBV is less volatile compared to CTOR. This indicates lower risk in terms of short-term price fluctuations for ABBV.Check CTOR's competition here
Scilex Holding Company (NASDAQ: SCLX)
ABBV vs SCLX Comparison August 2026
AbbVie Inc. (NYSE: ABBV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 457.5B. In comparison, SCLX has a market cap of 53.8M. Regarding current trading prices, ABBV is priced at $262.69 on the NYSE, while SCLX trades at $6.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 25.41, whereas SCLX's P/E ratio is -0.16. In terms of profitability, ABBV's ROE is -1.36%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, ABBV is less volatile compared to SCLX. This indicates lower risk in terms of short-term price fluctuations for ABBV.Check SCLX's competition here
Scilex Holding Company (NASDAQ: SCLXW)
ABBV vs SCLXW Comparison August 2026
AbbVie Inc. (NYSE: ABBV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 457.5B. In comparison, SCLXW has a market cap of 44.7M. Regarding current trading prices, ABBV is priced at $262.69 on the NYSE, while SCLXW trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 25.41, whereas SCLXW's P/E ratio is N/A. In terms of profitability, ABBV's ROE is -1.36%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, ABBV is less volatile compared to SCLXW. This indicates lower risk in terms of short-term price fluctuations for ABBV.Check SCLXW's competition here
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA)
ABBV vs MIRA Comparison August 2026
AbbVie Inc. (NYSE: ABBV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 457.5B. In comparison, MIRA has a market cap of 32.1M. Regarding current trading prices, ABBV is priced at $262.69 on the NYSE, while MIRA trades at $0.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 25.41, whereas MIRA's P/E ratio is -0.53. In terms of profitability, ABBV's ROE is -1.36%, compared to MIRA's ROE of -1.07%. Regarding short-term risk, ABBV is less volatile compared to MIRA. This indicates lower risk in terms of short-term price fluctuations for ABBV.Check MIRA's competition here
BioDelivery Sciences Intl, Inc. Wrrt (NASDAQ: BDSIW)
ABBV vs BDSIW Comparison August 2026
AbbVie Inc. (NYSE: ABBV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 457.5B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, ABBV is priced at $262.69 on the NYSE, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 25.41, whereas BDSIW's P/E ratio is -0.43. In terms of profitability, ABBV's ROE is -1.36%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, ABBV is less volatile compared to BDSIW. This indicates lower risk in terms of short-term price fluctuations for ABBV.Check BDSIW's competition here
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT)
ABBV vs CRXT Comparison August 2026
AbbVie Inc. (NYSE: ABBV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBV stands at 457.5B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, ABBV is priced at $262.69 on the NYSE, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBV currently has a P/E ratio of 25.41, whereas CRXT's P/E ratio is -0.02. In terms of profitability, ABBV's ROE is -1.36%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, ABBV is less volatile compared to CRXT. This indicates lower risk in terms of short-term price fluctuations for ABBV.Check CRXT's competition here